Clinical Trial Search

Primary: Subjects With Investigator Global Assessment (IGA) Success (IGA of 0 or 1) at End of Treatment (Day 7 or 14). — 91.7; 96 percentage of participants — p=>0.05

Primary: Efficacy Determined Using the Investigator's Global Assessment (IGA) - Adult — 2.1; 1.1 units on a scale — p=<0.001

Primary: Total Severity Score (TSS): Percent Change From Baseline at Week 4 — -71.4; -66.7; -66.7; -57.1 Percent change — p=<0.01

Primary: Percent Change in ISGA (Investigator's Static Global Assessment) Score — 67.8 percent change

Primary: Feasibility and Safety — 7; 1 count

Primary: Eczema Area and Severity Index (EASI) on Day 3 - Change From Baseline — -1.783; -0.767 units on a scale — p=<0.0001

Primary: Provider-diagnosed Atopic Dermatitis — 217.7; 268.5 Participants with imputed values — p=0.019

Primary: Success of Investigator's Global Assessment (IGA) — 3; 7 Participants

Primary: The Change of F-IGA From Baseline (BL) to wk 1 Will be the Primary Efficacy Variable. — -0.9; -0.6 units on a scale — p=.009

Primary: Percentage of Subjects Preffering Clobetasol Propionate Shampoo Better Than Comparator — 28.5; 31.6; 21.8 Percentage of participants — p=0.0003

Primary: Percentage of Participants With Cumulative Atopic Dermatitis Diagnosed by Investigator at 12 Months — 13.2; 25 Percentage of participants

Primary: Efficacy of NatrOVA Creme Rinse - 1% Relative to NIX Creme Rinse in Subjects Infested With Head Lice — 72; 17; 36; 11 participants

Primary: Efficacy of NatrOVA Creme Rinse - 1% Relative to NIX Creme Rinse in Subjects Infested With Head Lice — 77; 19; 40; 14 participants

Primary: Percentage Change From Baseline in Psoriasis Scalp Severity Index at Week 12 — 20.4; 86.8 Percent change — p=<0.0001

Primary: Number of Participants With Improved Skin Moisturization — 114 Participants

Primary: The Number of Days Free From Diaper Dermatitis — 4.065; 4.274 Days

Primary: Number of Participants With Adverse Events (AEs) in Part 1 of Trial (Weeks 0-8) — 7; 7; 5; 5 participants

Primary: Subjective Subject Preference Survey for the First Treatment Session — 81.1; 77.6 units on a scale

Primary: Incidence of Skin Irritation — 0 Participants

Primary: Number of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Site Reactions — 88; 1; 15 Participants

Primary: Steroid Usage Quantity — 7.27; 10.78; 8.22 grams

Primary: Number of Participants That Experienced Adverse Events (AEs) and Serious Adverse Events (SAEs) — 8; 0 Participants

Primary: Number of Participants With HPA Axis Suppression — 0; 2 Participants

Primary: Time to Relapse (Quantile 25%) — 48; 15 Days

Primary: Change From Baseline in Three Item Severity Score — -2.6; -3.6 units on a scale

Primary: Tolerability Assessment of Test Products — 9; 10; 11; 1 Participants

Primary: Proportion of Patients in Each Treatment Group Who Are Considered a Clinical Success — 49; 41 Participants — p=0.2961